Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial

BMJ 2010; 341 doi: (Published 20 July 2010)
Cite this as: BMJ 2010;341:c3493

Related articles

Data supplement

Web Extra

Web Extra

See more

Research News: Young women most at risk are least likely to be offered HPV vaccine

News: FDA panel recommends DNA test as first line cervical cancer screening test

Research News: HPV vaccine protects against cervical abnormalities in young women, study finds

Letter: More education is needed before we burden women with their HPV status

News: In brief

This article has been cited by other articles: